Harnessing the benefits of continuous crystallization to precisely control particular size distribution of active pharmaceutical ingredients

点击翻译按钮获取中文摘要

Control of crystallite particle size distribution is essential in the manufacturing of pharmaceutical dosageforms. In particular, obtaining a narrow size distribution is essential to enable new sustained release technologydeveloped by Eupraxia pharmaceuticals. The present workflow presents a significant barrier to scale up andmanufacturing of a novel anti-inflammatory therapy. New techniques designed by the Hein lab, whichleverages automation and in situ monitoring technology, will help to identify optimal crystallization conditionsto achieve a narrow and controlled particle size distribution for the active pharmaceutical ingredient. Inaddition, the Hein lab will investigate adapting the optimized crystallization process into a continuouscrystallization workflow, making the final manufacturing stage robust and very efficient.